Voya Investment Management LLC Reduces Stock Holdings in Vanda Pharmaceuticals Inc. $VNDA

Voya Investment Management LLC lowered its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 14.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,896 shares of the biopharmaceutical company’s stock after selling 2,579 shares during the quarter. Voya Investment Management LLC’s holdings in Vanda Pharmaceuticals were worth $73,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in VNDA. Millennium Management LLC lifted its position in Vanda Pharmaceuticals by 220.0% during the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after buying an additional 1,470,898 shares during the period. Nuveen LLC bought a new stake in Vanda Pharmaceuticals in the 1st quarter worth about $2,022,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Vanda Pharmaceuticals in the first quarter worth about $875,000. GSA Capital Partners LLP boosted its position in Vanda Pharmaceuticals by 88.0% in the first quarter. GSA Capital Partners LLP now owns 260,215 shares of the biopharmaceutical company’s stock worth $1,194,000 after purchasing an additional 121,797 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Vanda Pharmaceuticals by 13.5% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 929,644 shares of the biopharmaceutical company’s stock worth $4,267,000 after purchasing an additional 110,262 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on VNDA. Wall Street Zen cut Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 2nd. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Thursday, August 21st. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Strong Buy” and a consensus target price of $16.50.

Vanda Pharmaceuticals Price Performance

Shares of VNDA opened at $5.10 on Thursday. The stock has a market capitalization of $301.36 million, a price-to-earnings ratio of -4.51 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a 1 year low of $3.81 and a 1 year high of $5.55. The business’s 50 day simple moving average is $4.57 and its 200-day simple moving average is $4.53.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.12). The firm had revenue of $52.59 million for the quarter, compared to analysts’ expectations of $54.77 million. Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.